Vertex Pharmaceuticals (VRTX) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Vertex Pharmaceuticals Incorporated (VRTX) insider buying and selling: no purchases, 60 sales
146 Form 4 Table I transactions filed with the SEC by Vertex Pharmaceuticals Incorporated insiders between 2025-08-29 and 2026-09-10 (15-month history): 0 open-market purchases and 60 sales, plus 86 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $28.7M by Leiden Jeffrey M on 2025-12-03.
Vertex Pharmaceuticals insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Vertex Pharmaceuticals insiders filed 58 sales worth $158.1M on the open market, and no purchases.
The biggest seller was Leiden Jeffrey M (Executive Chairman): $60.9M in 3 sales, out of 13 different sellers.
The largest trade of the period was a sale of $28.7M on Dec 3, 2025, by Leiden Jeffrey M (Executive Chairman), under a 10b5-1 plan. Form 4 on sec.gov (0000875320-25-000242).
All 58 sales carry the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 0 sales, against 14 in the three before. The latest sale from Jul 2, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Vertex Pharmaceuticals has more sales than 57 of the other 58, ranks 7 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with VRTX's sales, largest first. The full history is in the tool above, already searched.
See all 146 VRTX trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-12-03 | 2025-12-05 | Leiden Jeffrey M | Executive Chairman | $28.7M | S — Open-market sale (scheduled 10b5-1)14 Form 4 footnotesF1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025. F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00). F4 Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00). F5 Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93). F6 Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94). F7 Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82). F8 Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23). F9 Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12). F10 Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18). F11 Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70). F12 Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69). F13 Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70). F14 Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66). | SEC |
| 2026-02-19 | 2026-02-23 | Sachdev Amit | EVP Chief Patient & Ext Af Off | $27.5M | S — Open-market sale (scheduled 10b5-1)10 Form 4 footnotesF1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F2 Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28). F3 Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46). F5 Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49). F6 Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05). F7 Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09). F8 Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05). F9 Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08). F10 Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03). | SEC |
| 2025-11-14 | 2025-11-17 | Leiden Jeffrey M | Executive Chairman | $23.6M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025. F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99). F6 Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99). | SEC |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | $19.7M | S — Open-market sale (scheduled 10b5-1)15 Form 4 footnotesF1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). F4 Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). F5 Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). F6 Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). F7 Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). F8 Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). F9 Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). F10 Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). F11 Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). F12 Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). F13 Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). F14 Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). F15 Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17). | SEC |
| 2025-11-13 | 2025-11-17 | Leiden Jeffrey M | Executive Chairman | $8.7M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025. F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99). F4 Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10). | SEC |
| 2025-12-03 | 2025-12-05 | Wagner Charles F Jr | EVP, CO & FO | $6.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/9/2025. | SEC |
| 2026-01-06 | 2026-01-08 | Wagner Charles F Jr | EVP, CO & FO | $4.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/09/2025. | SEC |
| 2026-05-12 | 2026-05-14 | Bozic Carmen | EVP and CMO | $3.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. | SEC |
| 2026-02-25 | 2026-02-26 | Mckechnie Duncan | EVP, Chief Commercial Officer | $2.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. | SEC |
| 2026-01-07 | 2026-01-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | $2.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. | SEC |
| 2025-12-03 | 2025-12-05 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | $2.0M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. F2 Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00). F3 Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. | SEC |
| 2026-06-15 | 2026-06-17 | Bozic Carmen | EVP and CMO | $1.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. | SEC |
| 2026-03-11 | 2026-03-13 | Mckechnie Duncan | EVP, Chief Commercial Officer | $1.3M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. | SEC |
| 2026-02-17 | 2026-02-19 | Biller Jonathan | EVP and Chief Legal Officer | $1.2M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. | SEC |
| 2026-02-17 | 2026-02-19 | Bunnage Mark E. | EVP, Chief Scientific Officer | $1.2M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. | SEC |
| 2026-03-04 | 2026-03-06 | Mckechnie Duncan | EVP, Chief Commercial Officer | $1.2M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. | SEC |
| 2026-03-13 | 2026-03-17 | Bozic Carmen | EVP and CMO | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. | SEC |
| 2026-02-27 | 2026-03-03 | Bozic Carmen | EVP and CMO | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. | SEC |
| 2025-11-17 | 2025-11-19 | Atkinson Edward Morrow Iii | EVP, Chief Technical Ops. Off. | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. | SEC |
| 2026-03-27 | 2026-03-31 | Bozic Carmen | EVP and CMO | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 29, 2025 and Sep 10, 2026 there is not one open-market purchase of Vertex Pharmaceuticals Incorporated: 60 sales worth $158.5M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Vertex Pharmaceuticals Incorporated's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| S | Open-market sale | 60 | $158.5M |
| F | Tax withholding (shares surrendered for taxes) | 43 | $51.8M |
| A | Grant or award | 31 | $0 |
| M | Option exercise | 6 | $22.2M |
| D | Sale back to the issuer | 4 | $0 |
| G | Gift | 2 | $0 |
| Total | Everything filed in the period | 146 | $232.4M |
37 of the 146 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 22 distinct people or entities have filed Vertex Pharmaceuticals Incorporated transactions: none bought on the open market and 13 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 13 who sold on the open market (60 sales in all), the three biggest sellers account for $109.1M of the $158.5M: 69% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Leiden Jeffrey M | Executive Chairman | 11 | — | $60.9M (3) | 2026-02-26 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 10 | — | $28.4M (2) | 2026-07-23 |
| Kewalramani Reshma | CEO & President | 7 | — | $19.7M (1) | 2026-03-03 |
| Bozic Carmen | EVP and CMO | 16 | — | $11.3M (10) | 2026-06-30 |
| Wagner Charles F Jr | EVP, CO & FO | 9 | — | $10.8M (2) | 2026-02-26 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 15 | — | $6.5M (8) | 2026-07-23 |
| Mckechnie Duncan | EVP, Chief Commercial Officer | 10 | — | $5.7M (4) | 2026-07-07 |
| Biller Jonathan | EVP and Chief Legal Officer | 14 | — | $4.1M (7) | 2026-02-26 |
Shown here are the 8 who moved the most money, out of 22. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 0 purchases and 29 sales, worth $64.4M. 4 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $103k |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 1 | $281k |
| Nov 2025 | 0 | $0 | 3 | $33.4M |
| Dec 2025 | 0 | $0 | 4 | $37.2M |
| Jan 2026 | 0 | $0 | 2 | $6.5M |
| Feb 2026 | 0 | $0 | 29 | $64.4M |
| Mar 2026 | 0 | $0 | 5 | $5.1M |
| Apr 2026 | 0 | $0 | 1 | $439k |
| May 2026 | 0 | $0 | 6 | $5.3M |
| Jun 2026 | 0 | $0 | 5 | $3.7M |
| Jul 2026 | 0 | $0 | 3 | $2.0M |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Vertex Pharmaceuticals Incorporated (VRTX) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
20 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Vertex Pharmaceuticals has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Sep 10, 2026, and a Form 4 arrives up to two business days after the trade.
20 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.